Return to homepagePandemic Pact

Seroprevalence against SARS-CoV-2 in pregnant women and newborns

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00923

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Javier Llorca Díaz, María Jesús Cabero Pérez

  • Research Location

    Spain

  • Lead Research Institution

    FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA (IDIVAL)

  • Research Priority Alignment

    N/A

  • Research Category

    Epidemiological studies

  • Research Subcategory

    Disease susceptibility

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)Newborns (birth to 1 month)

  • Vulnerable Population

    Pregnant womenOther

  • Occupations of Interest

    Unspecified

Abstract

Cohort study including 1000 pregnant women and their 1000 newborns in the community of Cantabria, which will be followed for one year. IgG and IgM anti-SARS-CoV-2 determinations will be made in the mother at the first pregnancy visit, on the day of delivery and at 6 and 12 months after delivery; in the newborn on the day of birth and at 6 and 12 months. Sociodemographic information and the process of care for pregnancy and childbirth will be collected. At follow-up, the newborn's somatometry and psychomotor development will be evaluated.